Zura Bio begins Phase 2 study for systemic sclerosis treatment - Investing.com

Zura Bio Limited initiates Phase 2 TibuSURE trial to evaluate tibulizumab in systemic sclerosis, targeting IL-17A and BAFF. The study aims to address unmet medical needs with a 24-week efficacy period and a 28-week extension. Zura Bio maintains strong financial health and plans additional trials for hidradenitis suppurativa.